Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.

EP: 1.Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC

EP: 2.SunRISe-1: Examining Combination Therapy for HR NMIBC

EP: 3.NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

Now Viewing

EP: 4.Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

EP: 5.SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer

EP: 6.Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations

EP: 7.Final Insights on Current Bladder Cancer Clinical Trials

Video content above is prompted by the following question(s):

• What are the potential advantages of the novel gene therapy nadofaragenefiradenovec compared to standard-of-care therapies for patients with BCG-unresponsive NMIBC? Discuss the clinical significance of the 5-year bladder preservation and overall survival rates reported.

Related Videos

Related Content

Advertisement

January 25th 2025

Zongertinib Offers “The Best Toxicity Profile I Have Ever Seen,” Santos Says

Interview by Mary Caffrey

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

January 20th 2025

Effects of Individualized Nurse-Led Care Plans on Olaparib Treatment Duration

Denise Tran, PharmD Haesuk Park, PhD Jordon Rabey, MS Seth Killion, BS S. Bobby Arelli, MD Elaine Murphy, BS Yoona Kim, PharmD, PhD

A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

January 13th 2025

Lung Cancer Screening Facilities Least Accessible to American Indian/Alaska Native Patients, Rural Communities

Brooke McCormick

Some populations face significant disparities in accessing lung cancer screening facilities, with American Indian/Alaska Native (AI/AN)-majority and rural census tracts facing the greatest travel distances.

January 13th 2025

Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

Brooke McCormick

Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.

Related Content

Advertisement

January 25th 2025

Zongertinib Offers “The Best Toxicity Profile I Have Ever Seen,” Santos Says

Interview by Mary Caffrey

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

January 20th 2025

Effects of Individualized Nurse-Led Care Plans on Olaparib Treatment Duration

Denise Tran, PharmD Haesuk Park, PhD Jordon Rabey, MS Seth Killion, BS S. Bobby Arelli, MD Elaine Murphy, BS Yoona Kim, PharmD, PhD

A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

January 13th 2025

Lung Cancer Screening Facilities Least Accessible to American Indian/Alaska Native Patients, Rural Communities

Brooke McCormick

Some populations face significant disparities in accessing lung cancer screening facilities, with American Indian/Alaska Native (AI/AN)-majority and rural census tracts facing the greatest travel distances.

January 13th 2025

Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

Brooke McCormick

Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.